23 Sep. 2025
Foresee Pharmaceuticals Announce syMMPonia Abstract Presentation at European Respiratory Society (ERS) Congress 
29 Aug. 2025
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer
17 Jun. 2025
Foresee Pharmaceuticals announces reaching a significant milestone, of complete enrollment of its Phase 3 Casppian trial for patients with Central Precocious Puberty (CPP)
14 May. 2025
Foresee Pharmaceuticals Announces a Keynote Oral Presentation and Participation at the 2025 American Thoracic Society International Conference
14 May. 2025
Foresee Pharmaceuticals Announces First Patient Dosed in the Phase 2 WINDWARD Study of the ALDH2 Activator Mirivadelgat for Patients with Pulmonary Hypertension-Associated Interstitial Lung Disease (PH-ILD)
17 Feb. 2025
